

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
It contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no responses are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2**

of **3**

Complete if Known

Application Number	
Filing Date	07/18/2001
First Named Inventor	R. Rex Denton
Group Art Unit	
Examiner Name	
Attorney Docket Number	MWH-008US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BA		ADAMCZEWSKI, M. ET AL., "Expression and Biological Effects of High Levels of Serum IgE in Epsilon Heavy Chain Transgenic Mice," European Journal of Immunology, Vol. 21, p. 617-626, (1991).	
BB		COX, H.E. ET AL., "Association of Atopic Dermatitis to the Beta Subunit of the High Affinity Immunoglobulin E Receptor," British Journal of Dermatology, Vol. 138, p. 182-187, (1998).	
BC		DIAZ-SANCHEZ, A.S. ET AL., "Regulation of the Expression of Distinct Human Secreted IgE Proteins Produced by Alternative RNA Splicing" in Immunological Intervention Strategies in Allergy Biochemical Society Transactions, Vol. 25, (No. 25) p. 383-387, (1997).	
BD		DICKSON, PHILLIP W. ET AL., "Mutational Analysis of the High Affinity Immunoglobulin E Receptor B Subunit Gene in Asthma," Thorax, Vol. 54, p. 409-412, (1999).	
BE		HILL AND COOKSON, "A New Variant of the B Subunit of the High-Affinity Receptor for Immunoglobulin E (FCER1-B E237G): Associations with Measures of Atopy and Bronchial Hyper-Responsiveness," Human Molecular Genetics, Vol. 5, p. 959-962, (1996).	
BF		HIZAWA, NOBUYUKI ET AL., "A Common FCER1B Gene Promoter Polymorphism Influences Total Serum IgE Levels in a Japanese Population," Am J Respi Crit Care Med, Vol. 161, p. 906-909, (2000).	
BG		KINET, J.P. ET AL., "Isolation and Characterization of cDNA's Coding for the B-Subunit of the High-Affinity Receptor for Immunoglobulin E. Proceedings of the National Academy of Sciences," PNAS, Vol. 85, p. 6483-6487, (1998).	
BH		PALMER, L.J. ET AL., "FCER1-B Polymorphisms and Total Serum IgE Levels in Endemically Parasitized Australian Aborigines," Am. J. Hum. Genet., Vol. 61, p. 182-188, (1997).	
BI		RIVERA, J. ET AL., "Studies with a Monoclonal Antibody to the BSubunit of the Receptor with High Affinity for Immunoglobulin E," Molecular Immunology, Vol. 25 (No. 7), p. 547-661, (1988).	
BJ		SATO, T. ET AL., "A New Method for Studying the Binding of Human IgE to CD23 and the Inhibition of this Binding," Journal of Immunological Methods, Vol. 209, p. 59-66, (1997).	
BK		SHIRAKAWA, TARO ET AL., "Association between Atopy and Variants of the B Subunit of the High-Affinity Immunoglobulin E Receptor," Nature Genetics, Vol. 7, p. 125-130, (1994).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995,

Persons are required to respond to a collection of information

It contains a valid OMB control number.

Complete if Known

Application Number

Filing Date

07/18/2001

First Named Inventor

R. Rex Denton

Group Art Unit

Examiner Name

Attorney Docket Number

MWH-008US

(use as many sheets as necessary)

Sheet

13

of

3

Examiner
Initials*

Cite
No.¹

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

T2

BL SHIRAKAWA, T. ET AL., "Association between Atopic Asthma and a Coding Variant of FCER1B in a Japanese Popoulation," Human Molecular Genetics, Vol. 5, p. 1129-1130, (1996).

BM	WITTHUHN B. A., ET AL., "Isolation and Characterization of the Rat B-Subunit Gene of the High Affinity Receptor for Immunoglobulin E," Molecular Immunology, Vol. 33, (No. 10), p. 881-890
----	--

Examiner
Signature

Date _____

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**